|
|
Press Releases
| All 2007 Releases |
|---|
 |
Osiris Therapeutics Completes $12 Million Private Placement and Eliminates $19 Million of Debt Through Common Stock Conversion
12-20-07
11.6 KB
|
| |
COLUMBIA, Md., Dec 20, 2007 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading stem cell therapeutic company, announced today that it has closed an $11.8 million private placement of its common stock and eliminated through conversion, $18.8 million of debt. No fees or commissions were paid in either transaction.
On December ...
|
|
Osiris Therapeutics Reports Positive Results for Prochymal(TM) as a Rescue Agent in Pediatric Patients with End-Stage Graft vs. Host Disease
12-10-07
13.5 KB
|
| |
COLUMBIA, Md., Dec 10, 2007 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) announced today results from the Company's compassionate use evaluation of Prochymal, an adult stem cell therapy, for the treatment of pediatric patients suffering from end-stage graft versus host disease (GvHD). Complete disease resolution was achieved in 58% of...
|
|
Osiris Therapeutics Receives FDA Fast Track Status for Prochymal(TM) as First-Line Treatment for Acute GvHD
12-07-07
15.1 KB
|
| |
COLUMBIA, Md., Dec 07, 2007 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) announced today that Prochymal(TM) has received Fast Track designation from the U.S. Food and Drug Administration (FDA), expediting development of the stem cell therapy as a first-line agent for acute Graft versus Host Disease (GvHD). A Phase III pivotal study fo...
|
|
Osiris Therapeutics Announces Positive One Year Data from Chondrogen Trial for Knee Repair
11-27-07
15.1 KB
|
| |
COLUMBIA, Md., Nov 27, 2007 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) announced positive one-year interim results in the evaluation of Chondrogen, a preparation of adult stem cells formulated for direct injection into the knee. The one year data showed improvement in joint condition that correlated with a clinically and statistical...
|
|
Osiris Therapeutics to Present at the 19th Annual Piper Jaffray Health Care Conference
11-26-07
8.9 KB
|
| |
COLUMBIA, Md., Nov 26, 2007 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas, announced today that C. Randal Mills, Ph.D., President and CEO, is scheduled to present at...
|
|
Osiris Therapeutics Announces Management Change
11-23-07
9.5 KB
|
| |
COLUMBIA, Md., Nov 23, 2007 (BUSINESS WIRE) -- Osiris Therapeutics (Nasdaq: OSIR) announced today that Cary J. Claiborne, Chief Financial Officer, has left the Company effective today, to pursue new professional opportunities. Mr. Claiborne will be available to provide transition assistance to Osiris through March 31, 2008.
"We want to thank Ca...
|
|
Osiris Therapeutics Reports Third Quarter 2007 Financial Results
11-12-07
19.0 KB
|
| |
COLUMBIA, Md., Nov 12, 2007 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas, announced today its results for the third quarter ended September 30, 2007. For the quarter...
|
|
Osiris Announces Third Quarter 2007 Financial Results Conference Call
11-08-07
9.6 KB
|
| |
COLUMBIA, Md., Nov 08, 2007 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas, announced today that it will report its financial results for the quarter ended September ...
|
|
Osiris Therapeutics to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
11-06-07
8.9 KB
|
| |
COLUMBIA, Md., Nov 06, 2007 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas, announced today that C. Randal Mills, Ph.D., President and CEO, is scheduled to present at...
|
|
Osiris Therapeutics Initiates Phase II Clinical Trial Evaluating Prochymal(TM) for Type 1 Diabetes
10-25-07
16.1 KB
|
| |
COLUMBIA, Md., Oct 25, 2007 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced the initiation of a Phase II clinical trial evaluating Prochymal, a stem cell therapy, as a treatment for type 1 diabetes. Through a partnership with the Juvenile Diabetes Research Foundation (JDRF), the organization has provided $4 million in fun...
|
|
|
 |
Stock Information
OSIR - (NASDAQ)
$6.57
+ 0.09
|
11-20-09
4:11 PM ET
Quotes delayed at least 20 minutes. Information provided by eSignal.
|
|
|
|
|
Shareholder Tools
|
|
